We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

98 hedge funds and large institutions have $85.5M invested in Endocyte, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

0% more funds holding

Funds holding: 9898 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

22% less capital invested

Capital invested by funds: $109M → $85.5M (-$23.5M)

27% less call options, than puts

Call options by funds: $936K | Put options by funds: $1.28M

Holders
98
Holders Change
Holders Change %
0%
% of All Funds
2.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
38
Reduced
25
Closed
9
Calls
$936K
Puts
$1.28M
Net Calls
-$342K
Net Calls Change
+$148K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$19.8M -$6.61M -1,101,850 -22%
BFA
2
BlackRock Fund Advisors
California
$7.83M -$367K -61,159 -4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6M +$472K +78,723 +7%
HCMT
4
Highland Capital Management (Texas)
Texas
$5.1M -$104K -17,346 -2%
PA
5
Pinnacle Associates
New York
$5M -$203K -33,900 -3%
Millennium Management
6
Millennium Management
New York
$4.07M -$151K -25,225 -3%
State Street
7
State Street
Massachusetts
$4.02M +$196K +32,724 +4%
NI
8
Numeric Investors
Massachusetts
$3.4M +$602K +100,297 +18%
Northern Trust
9
Northern Trust
Illinois
$2.14M +$119K +19,891 +5%
Renaissance Technologies
10
Renaissance Technologies
New York
$2M +$42.1K +7,012 +2%
BIT
11
BlackRock Institutional Trust
California
$1.82M -$219K -36,452 -9%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$1.35M +$150K +25,049 +11%
OAM
13
Oxford Asset Management
United Kingdom
$1.28M +$108K +18,036 +8%
Deutsche Bank
14
Deutsche Bank
Germany
$1.24M +$290K +48,327 +25%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.21M +$177K +29,480 +14%
CRC
16
Curi RMB Capital
Illinois
$1.14M
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$1M +$670K +111,702 +138%
BCM
18
Bridgeway Capital Management
Texas
$908K +$300K +50,000 +40%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$856K
BAMS
20
Bellevue Asset Management (Switzerland)
Switzerland
$820K -$193K -32,215 -17%
TCIM
21
TIAA CREF Investment Management
New York
$811K +$92.4K +15,412 +11%
BIM
22
BlackRock Investment Management
Delaware
$775K +$239K +39,890 +36%
Charles Schwab
23
Charles Schwab
California
$743K +$24.1K +4,023 +3%
Morgan Stanley
24
Morgan Stanley
New York
$671K +$193K +32,145 +33%
MERSOM
25
Municipal Employees' Retirement System of Michigan
Michigan
$610K

ECYT Hedge Fund Activity: Q2 2015 in Review

98 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2015, worth a combined $85.5M — down 22% from $109M a quarter earlier.

Fund positioning in ECYT was balanced in Q2 2015: 9 funds opened new positions, 9 closed out, 38 added to existing stakes and 25 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $670K. The largest seller was Fidelity Investments, cutting an estimated $6.61M.

  • 98 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2015, unchanged from Q1 2015.
  • Funds reported $85.5M of Endocyte, Inc. Common Stock stock for Q2 2015, down 22% quarter-over-quarter.
  • 9 funds opened new Endocyte, Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of 0 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q2 2015 was Royal Bank of Canada, an estimated $670K added.
  • The largest Endocyte, Inc. Common Stock seller in Q2 2015 was Fidelity Investments, an estimated $6.61M sold.

Based on aggregated 13F filings for Q2 2015.